Delamanid 1 is an antibiotic developed by Otsuka pharmaceuticals for the treatment of multidrug-resistant tuberculosis (TB), and was added to the World Health Organisation's (WHO) list of essential medicines in 2015. Unfortunately, in regions of the world most affected by TB, access to this important therapy remains limited due to the high cost of the drug. Therefore, the development of an economical and efficient manufacturing route for delamanid is vital in order to allow the widest possible access to the treatment.